Compare Ishares Msci Italy ETF (EWI) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Zoetis Inc — how do they compare? Ishares Msci Italy ETF trades at $56.15 (market cap $1.14B), while Zoetis Inc trades at $74.33 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 26.5× Ishares Msci Italy ETF's market cap, and Zoetis Inc pays a 2.9% dividend while Ishares Msci Italy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 52 Days and Zoetis Inc for 70 Days on average.
| EWI | ZTS | |
|---|---|---|
Market Cap | $1.14B | $30.20B |
Volume | 2,377,947 | 6,175,327 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $147.53 |
52-Week Low | $50.31 | $69.09 |
Typical Hold Time | 52 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.35, down 2.74% on the day, reflecting a bearish technical outlook with all moving averages signaling sell. The ETF provides exposure to Italian financials, utilities, and industrials, benefiting from EU recovery investments and sector consolidation. Recent news highlights ECB rate hikes and eurozone economic concerns, with energy-driven inflation posing headwinds.
The outlook remains cautious due to macroeconomic pressures from rising interest rates and inflation, though structural investments in Italian infrastructure offer long-term potential. Key risks include eurozone volatility and energy price shocks, while technical indicators suggest near-term weakness. Investors should weigh sector-specific strengths against broader market sentiment.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
